News
Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote
An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti
